Are Metastatic Breast Cancer Patients Getting the Right Treatment?

New research shows some metastatic breast cancer patients could be receiving the wrong treatment.

BY MELISSA WEBER
PUBLISHED: SEPTEMBER 17, 2010
As many as one in seven women with metastatic breast cancer could be receiving the wrong treatment because of a change in the cancer’s biology when it metastasizes, according to new research.

When breast cancer spreads to another part of the body, a HER2-positive cancer could become HER2-negative. Or estrogen receptor-negative cancer could switch to estrogen receptor-positive. Despite different treatment strategies for each, most oncologists rely on what they know about the primary breast tumor to fight the metastasis, says Giuseppe Curigliano, MD, PhD, co-director of the division of medical oncology at the European Institute of Oncology in Milan, Italy. But researchers now believe inhibiting one cancer growth pathway with treatment may activate signaling of a new pathway that allows it to survive and spread.

Although it’s not routine to biopsy metastatic lesions, pathologist Andrea Richardson, MD, PhD, says it has become more of the norm at Brigham and Women’s Hospital in Boston, where she works. “Our oncologists are much more likely to rebiopsy these if it’s not too risky for the patient. But that’s certainly not the case in small community hospitals and not worldwide either,” says Richardson, who also serves as an assistant professor of pathology at Harvard Medical School.

In a study presented this summer at the annual meeting of the American Society of Clinical Oncology, researchers compared biopsy data from 255 women with breast cancer that had spread to the liver after a median time of about three and a half years since the primary diagnosis. The question was, did the cancer’s estrogen, progesterone, and HER2 receptor status—factors that helped determine the correct course of treatment—remain the same? The cancer switched from estrogen receptor-negative to estrogen receptor-positive—or vice versa—in 37 patients (14.5 percent). When changes in HER2 status and progesterone status were also determined, a total of 31 patients (12.1 percent) changed treatment to match the cancer’s new biology.

“When safe and easy to perform, a biopsy of the metastatic lesion should be considered in all patients … since it is likely to impact treatment choice,” says Curigliano, who served as a co-investigator on the study.

You have to compare possibly being one of those people whose treatment would change versus the risk of doing the procedure.

In another study presented at the same meeting, researchers took tissue from 271 patients whose breast cancer had spread to locations such as the lymph node, liver, or skin. A median time of about six and a half years had passed between the primary cancer diagnosis and the metastatic recurrence biopsy. Forty-one women (15.1 percent) switched treatment after the features of the metastatic lesion didn’t match the primary tumor.

Richardson, who provided the analysis of the research after the two studies were presented, says the differences between primary and metastatic tumors may be related to the method used to test the tissue or how much of the tumor was sampled. But she admits the consistency of the discordant results in the studies suggests it’s a true biologic change.

Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.
x-button
 
CURE wants to hear from you! We are inviting you to Share Your Story with the readers of CURE. Submit your personal experience with cancer by visiting Share Your Story
 
Not yet receiving CURE in your mailbox? Sign up to receive CURE Magazine by visiting GetCureNow.com
x